|
KMID : 0988920220200040495
|
|
Intestinal Research
2022 Volume.20 No. 4 p.495 ~ p.505
|
|
|
Abdominal aortic calcification in patients with inflammatory bowel disease: does anti-tumor necrosis factor α use protect from chronic inflammation-induced atherosclerosis?
|
|
Mantaka Aikaterini
Galanakis Nikolaos
Tsetis Dimitrios
Koutroubakis Ioannis E.
|
|
|
Abstract
|
|
|
Background/Aims: Abdominal aortic calcium (AAC) deposition has been suggested as a marker of early atherosclerosis. There is no published data on the evaluation of AAC in inflammatory bowel disease (IBD).
Methods: AAC was quantified by computed tomography or enterography scans performed in 98 IBD patients and 1:1 age and sex matched controls. AAC deposition was correlated with IBD characteristics, disease activity or severity parameters, laboratory tests and cardiovascular disease (CVD) risk factors.
Results: Moderate-severe grade of AAC was found in 35.7% of IBD patients compared to 30.6% of controls (P=0.544). IBD with CVD and ulcerative colitis patients had significantly higher rates of more severe atherosclerotic lesions (P=0.001 and P=0.01, respectively). AAC deposition was similarly distributed in age groups (< 45, 45-64, and ≥ 65 years) among patients and controls. Multivariate analysis after excluding CVD risk confounders for non-CVD patients found extensive disease (P=0.019) and lifetime steroids (P=0.04) as independent risk factors for AAC. Anti-tumor necrosis factor α (TNF-α) use was negatively associated with AAC deposition in non-CVD IBD patients (odds ratio, 0.023; 95% confidence interval, 0.001-0.594; P=0.023).
Conclusions: More than one-third of IBD patients have moderate to severe AAC. Better control of inflammation with anti-TNF-α agents seems to protect IBD patients from ACC deposition and subsequent atherosclerosis.
|
|
|
KEYWORD
|
|
|
Abdominal aortic calcium, Atherosclerosis, Tumor necrosis factor-alpha, Crohn disease, Colitis, ulcerative
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|